Advertisement

Conservatively Managed Peyronie's Disease—Long-term Survey Results From Patients Undergoing Nonsurgical and Noninjection Therapies

Published:November 21, 2017DOI:https://doi.org/10.1016/j.urology.2017.11.012

      Objective

      To evaluate patient-reported temporal changes in penile curvature, pain, shortening, sexual function, and quality of life in men undergoing conservative treatment for PD.

      Materials and Methods

      Of 3840 patients who underwent evaluation at our institution between 1990 and 2012, 719 were randomly selected to receive a mail-in questionnaire with topics including penile curvature, pain, shortening, sexual function, and quality of life. Men endorsing prior intralesional or surgical therapy were excluded.

      Results

      A total of 125 patients completed the survey and met the inclusion criteria. The median duration between onset of PD symptoms and survey completion was 8.4 years. Overall, 38% felt that their condition had overall improved and 26% felt that their condition had worsened since onset. Penile curvature resolved in 43%, remained stable in 37%, and worsened in 20%. Twelve percent of the men developed a second de novo curvature. Penile pain occurred in 42%, among whom the pain worsened in 18% and completely resolved in 64%. Sixty-five percent reported penile shortening. Subjective erectile function decreased in 60%, and >40% experienced difficulties with penetrative intercourse. Sexual frequency decreased in 68% of the patients and 59% reported decreased relationship satisfaction. Approximately 50% described negative psychological impacts on self-esteem and image.

      Conclusion

      The current report provides the most comprehensive and longest-term data on patient-reported outcomes in men undergoing nonsurgical and noninjection therapies. Although approximately 40% of the men reported overall and curvature improvement at a median 8.4-year follow-up, penile length loss, worsening sexual function, relationship dissatisfaction, and psychosocial distress occurred in the majority of PD men.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brock G.
        • Hsu G.L.
        • Nunes L.
        • von Heyden B.
        • Lue T.F.
        The anatomy of the tunica albuginea in the normal penis and Peyronie's disease.
        J Urol. 1997; 157: 276-281
        • Kadioglu A.
        • Tefekli A.
        • Erol B.
        • Oktar T.
        • Tunc M.
        • Tellaloglu S.
        A retrospective review of 307 men with Peyronie's disease.
        J Urol. 2002; 168: 1075-1079
        • Arafa M.
        • Eid H.
        • El-Badry A.
        • Ezz-Eldine K.
        • Shamloul R.
        The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction.
        Int J Impot Res. 2007; 19: 213-217
        • Dibenedetti D.B.
        • Nguyen D.
        • Zografos L.
        • Ziemiecki R.
        • Zhou X.
        A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States.
        Adv Urol. 2011; 2011: 282503
        • Lindsay M.B.
        • Schain D.M.
        • Grambsch P.
        • Benson R.C.
        • Beard C.M.
        • Kurland L.T.
        The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984.
        J Urol. 1991; 146: 1007-1009
        • Mulhall J.P.
        • Creech S.D.
        • Boorjian S.A.
        • et al.
        Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.
        J Urol. 2004; 171: 2350-2353
        • La Pera G.
        • Pescatori E.S.
        • Calabrese M.
        • et al.
        Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years.
        Eur Urol. 2001; 40: 525-530
        • Mulhall J.P.
        • Schiff J.
        • Guhring P.
        An analysis of the natural history of Peyronie's disease.
        J Urol. 2006; 175 (discussion 2118): 2115-2118
        • Nelson C.J.
        • Mulhall J.P.
        Psychological impact of Peyronie's disease: a review.
        J Sex Med. 2013; 10: 653-660
        • Gelbard M.
        • Goldstein I.
        • Hellstrom W.J.
        • et al.
        Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.
        J Urol. 2013; 190: 199-207
        • Nehra A.
        • Alterowitz R.
        • Culkin D.J.
        • et al.
        Peyronie's disease: AUA guideline.
        J Urol. 2015; 194: 745-753
        • Sullivan J.
        • Moskovic D.
        • Nelson C.
        • Levine L.
        • Mulhall J.
        Peyronie's disease: urologist's knowledge base and practice patterns.
        Andrology. 2015; 3: 260-264
        • Chung E.
        • Brock G.
        Penile traction therapy and Peyronie's disease: a state of art review of the current literature.
        Ther Adv Urol. 2013; 5: 59-65
        • Gelbard M.K.
        • Dorey F.
        • James K.
        The natural history of Peyronie's disease.
        J Urol. 1990; 144: 1376-1379
        • Williams J.L.
        • Thomas G.G.
        The natural history of Peyronie's disease.
        J Urol. 1970; 103: 75-76
        • Berookhim B.M.
        • Choi J.
        • Alex B.
        • Mulhall J.P.
        Deformity stabilization and improvement in men with untreated Peyronie's disease.
        BJU Int. 2014; 113: 133-136
        • Bekos A.
        • Arvaniti M.
        • Hatzimouratidis K.
        • Moysidis K.
        • Tzortzis V.
        • Hatzichristou D.
        The natural history of Peyronie's disease: an ultrasonography-based study.
        Eur Urol. 2008; 53: 644-650
        • Grasso M.
        • Lania C.
        • Blanco S.
        • Limonta G.
        The natural history of Peyronie's disease.
        Arch Esp Urol. 2007; 60: 326-331
        • Rosen R.
        • Catania J.
        • Lue T.
        • et al.
        Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls.
        J Sex Med. 2008; 5: 1977-1984
        • Nelson C.J.
        • Diblasio C.
        • Kendirci M.
        • Hellstrom W.
        • Guhring P.
        • Mulhall J.P.
        The chronology of depression and distress in men with Peyronie's disease.
        J Sex Med. 2008; 5: 1985-1990
        • Frey A.U.
        • Sonksen J.
        • Fode M.
        Neglected side effects after radical prostatectomy: a systematic review.
        J Sex Med. 2014; 11: 374-385